NCT04290611View on ClinicalTrials.gov

a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY

CompletedOBSERVATIONAL
Enrollment

500,000

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2023

Study Completion Date

April 8, 2023

Conditions
Prostate CancerNeuropathyEpilepsyEncephalopathy
Interventions
DRUG

Enzalutamide

Enzalutamide for the treatment of prostate cancer or other solid tumors

Trial Locations (1)

75013

Centre d'Investigation Clinique Hôpital Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT04290611 - a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY | Biotech Hunter | Biotech Hunter